Stockscreener 앱 받기
2.14
1.42%
0.03
시간 외 거래:
2.05
-0.09
-4.21%
전일 마감가:
$2.11
열려 있는:
$2.08
하루 거래량:
273.28K
Relative Volume:
0.09
시가총액:
$7.33M
수익:
$3.57M
순이익/손실:
$-15.74M
주가수익비율:
-0.308
EPS:
-6.9481
순현금흐름:
$-15.77M
1주 성능:
-2.73%
1개월 성능:
-34.76%
6개월 성능:
-88.39%
1년 성능:
-92.87%
1일 변동 폭
$2.06
$2.20
1주일 범위
$2.06
$2.25
52주 변동 폭
$2.06
$42.00
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
2.14 | 7.23M | 3.57M | -15.74M | -15.77M | -6.9481 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Icecure Medical Ltd 주식(ICCM)의 최신 뉴스
ICCM Looks 89.8% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Icecure Medical Receives Regulatory Approval to Market Prosense in China - marketscreener.com
IceCure Medical (ICCM) secures China nod for tumor-freezing cancer tool - Stock Titan
China approves a tumor-freezing system from IceCure - Stock Titan
IceCure Medical Ltd. (ICCM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Icecure Medical Earnings Call Signals Early Growth Phase - TipRanks
IceCure and Scovas agree for ProSense distribution in Netherlands - Yahoo Finance
IceCure (ICCM) Results at a Glance: EPS Does Not Reach the Reported Estimate under the Current Snapshot; Post-Earnings: Shares Move 6.58% Down in Latest TradingTax Rate Impact - vinanet.vn
Icecure Medical Ltd. Signs Exclusive Distribution Agreement with Scovas Medical for Prosense Cryoablation Systems in the Netherlands - marketscreener.com
94% success breast cancer trial backs IceCure (ICCM) in new Dutch distribution push - Stock Titan
IceCure Medical (ICCM): Commercial Adoption Is Improving, but the Reimbursement and Scale Story Still Needs More Proof - AlphaStreet
ICCM Looks 87.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
IceCure says West Cancer Center IRB clears ChoICE breast cancer cryoablation study - Bitget
IceCure's ProSense Is First and Only for Low-Risk Breast Cancer With FDA Marketing Authorization - Stock Titan
Icecure Medical Ltd (ICCM) (Q2 2026) Earnings Call Highlights: R - GuruFocus
IceCure Medical (ICCM) Q2 2026 Earnings Call Transcript - AOL.ca
IceCure (ICCM) Earnings Report: EPS Misses Its Estimate under the Current Snapshot; Share Response - vinanet.vn
IceCure Medical Ltd. SEC Filing (Aug 19, 2026) - Stock Titan
IceCure Medical (ICCM) grants 131K RSUs to North America VP - Stock Titan
IceCure Medical : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
IceCure Medical (NASDAQ: ICCM) director lists no shares - Stock Titan
IceCure (NASDAQ: ICCM) VP now holds 106K shares and RSUs - Stock Titan
IceCure Medical (ICCM) awards COO 141K new RSUs - Stock Titan
IceCure Medical (NASDAQ: ICCM) adds 73,890 RSUs to VP HR stake - Stock Titan
IceCure Medical (ICCM) director Chan Vincent leaves board - Stock Titan
ICCM Looks 85.8% Undervalued on GF Value™ - GuruFocus
IceCure Medical (NASDAQ: ICCM) awards CFO 181K stock units at $0 - Stock Titan
IceCure Medical director David Salton files initial beneficial ownership statement - Bitget
IceCure Medical (ICCM) expands 2024 employee share incentive reserve - Stock Titan
Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control - Stock Titan
Maxim Group Maintains Icecure Medical(ICCM.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
IceCure Medical (ICCM) Earnings Call zum 2. Quartal 2026: Umsatz im 1. Halbjahr steigt um 45 % - TradingKey
IceCure Medical (ICCM) details 324,802-share warrant issuance and $9.7M potential proceeds - Stock Titan
New studies highlight FDA-approved ProSense cry... - pluang.com
Two papers examine tumor freezing beyond the primary breast tumor - Stock Titan
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation - PR Newswire
IceCure Medical regains Nasdaq bid price compliance - scanx.trade
IceCure Medical Q2 2026 Earnings Call Transcript - MarketBeat
IceCure sees Brazil adoption rise after FDA clearance - scanx.trade
IceCure Medical Ltd Q2 2026 Earnings Call Summary - Yahoo Finance
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year - GuruFocus
Earnings call transcript: IceCure Medical misses Q2 2026 estimates as shares fall - Investing.com
Icecure Medical Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
IceCure net loss widens to USD 8.78 million in H1 FY26; revenue rises 45% to USD 1.82 million - Bitget
IceCure Medical (Nasdaq: ICCM) lifts H1 revenue 45% but burns cash - Stock Titan
IceCure First-Half 2026 Earnings: 45% Revenue Growth Comes With Wider Losses - TradingKey
IceCure's Active U.S. Install Base Grows About 70%; Cash $12M - Stock Titan
Icecure Medical Q2 Results: EPS beats estimate, sales miss - scanx.trade
IceCure Medical (ICCM) names David Salton to board as independent director - Stock Titan
IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 (PR Newswire) - Aktiellt
Earnings To Watch: Icecure Medical Ltd (ICCM) Q2 2026 -- GF Value Sees 452% Upside - GuruFocus
Icecure Medical Ltd (ICCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.29%
0.75%
자본화:
|
볼륨(24시간):